CKD RISK and Adverse Events
A patient with a declining eGFR at risk for CV death increases in stage 3B by this amount.
What is 4x greater?
This patient has hypertension, an eGFR of 53 and is already on the maximum tolerated dose of ACEi/ARB.
Who is Lorraine?
This NNT was seen in DAPA-HF trial.
What is 21?
According to this diagram, a patient’s UACR greater than 30mg and an eGFR less than 60 is at risk for CKD.
What is the KDIGO Heatmap?
A severe life-threatening condition requiring immediate treatment. Symptoms include nausea, vomiting, abdominal pain, rapid breathing, and, in severe cases, unconsciousness
What is ketoacidosis?
This is the staggering number of Americans who have CKD.
What is 37 million
By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion.
What is the MOA of FX in diabetes
When a prescriber writes FX for CKD, they use this dose.
What is 10mg?
The percentage of patients in DAPA-CKD without T2D.
What is 32%
The percentage of patients diagnosed with CKD.
What is 10%
Farxiga reduces the pressure under which the heart fills (preload) and reduces the resistance against which the heart pumps (afterload).
What is the MOA of FX’s HF indication
T2D and high blood pressure are high risk factors for this disease.
A rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention.
What is Fournier’s Gangrene
This eGFR range defines the stage 3B CKD patient.
What is 30-44mL
Farxiga reduces glucose/sodium reabsorption, increases sodium to distal tubule, decreases intraglomerular pressure and increases glucose excretion.
What is the MOA for FX’s CKD indication
The percentage of patients in DAPA-CKD who were on an ACEi/ARB.
What is 97%
The percentage of patients in DAPA-CKD with T2D.
What is 68%
One of the reasons a patient should not be prescribed Farxiga.
What is dialysis
The significant RRR on mortality Farxiga showed in DAPA-CKD.
What is 31%
The primary outcome was the composite of sustained greater than or equal to 50% eGFR decline, ESKD, and renal or CV death.
What is the DAPA-CKD primary endpoint